Targeting SMO has emerged as a targeted treatment option for SHH-driven cancers including basal cell carcinoma [56] and recurrent SHH-MB [51, 52], demonstrating anti-tumor activity by suppressing SHH signaling. The gene discussed is SMO; the disease is neoplasm.